Literature DB >> 25955626

Lung cancer: diagnosis, treatment principles, and screening.

Kelly M Latimer1, Timothy F Mott1.   

Abstract

Lung cancer is classified histologically into small cell and non-small cell lung cancers. The most common symptoms of lung cancer are cough, dyspnea, hemoptysis, and systemic symptoms such as weight loss and anorexia. High-risk patients who present with symptoms should undergo chest radiography. If a likely alternative diagnosis is not identified, computed tomography and possibly positron emission tomography should be performed. If suspicion for lung cancer is high, a diagnostic evaluation is warranted. The diagnostic evaluation has three simultaneous steps (tissue diagnosis, staging, and functional evaluation), all of which affect treatment planning and determination of prognosis. The least invasive method possible should be used. The diagnostic evaluation and treatment of a patient with lung cancer require a team of specialists, including a pulmonologist, medical oncologist, radiation oncologist, pathologist, radiologist, and thoracic surgeon. Non-small cell lung cancer specimens are tested for various mutations, which, if present, can be treated with new targeted molecular therapies. The family physician should remain involved in the patient's care to ensure that the values and wishes of the patient and family are considered and, if necessary, to coordinate end-of-life care. Early palliative care improves quality of life and may prolong survival. Family physicians should concentrate on early recognition of lung cancer, as well as prevention by encouraging tobacco cessation at every visit. The U.S. Preventive Services Task Force recommends lung cancer screening using low-dose computed tomography in high-risk patients. However, the American Academy of Family Physicians concludes that the evidence is insufficient to recommend for or against screening. Whether to screen high-risk patients should be a shared decision between the physician and patient.

Entities:  

Mesh:

Year:  2015        PMID: 25955626

Source DB:  PubMed          Journal:  Am Fam Physician        ISSN: 0002-838X            Impact factor:   3.292


  36 in total

1.  Hypoxia-induced microRNA-301b regulates apoptosis by targeting Bim in lung cancer.

Authors:  Duoguang Wu; Baishen Chen; Fei Cui; Xiaotian He; Wenjian Wang; Minghui Wang
Journal:  Cell Prolif       Date:  2016-06-28       Impact factor: 6.831

2.  Diosmetin induces apoptosis and enhances the chemotherapeutic efficacy of paclitaxel in non-small cell lung cancer cells via Nrf2 inhibition.

Authors:  Xiangcui Chen; Qipeng Wu; Yueming Chen; Jiahao Zhang; Huachao Li; Zhicheng Yang; Yang Yang; Yanchao Deng; Luyong Zhang; Bing Liu
Journal:  Br J Pharmacol       Date:  2019-05-11       Impact factor: 8.739

Review 3.  Peroxiredoxins and Beyond; Redox Systems Regulating Lung Physiology and Disease.

Authors:  Evan A Elko; Brian Cunniff; David J Seward; Shi Biao Chia; Reem Aboushousha; Cheryl van de Wetering; Jos van der Velden; Allison Manuel; Arti Shukla; Nicholas H Heintz; Vikas Anathy; Albert van der Vliet; Yvonne M W Janssen-Heininger
Journal:  Antioxid Redox Signal       Date:  2019-04-05       Impact factor: 8.401

4.  Effects of miRNA-149-5p and Platelet-Activating Factor-Receptor Signaling on the Growth and Targeted Therapy Response on Lung Cancer Cells.

Authors:  Shreepa J Chauhan; Anita Thyagarajan; Ravi P Sahu
Journal:  Int J Mol Sci       Date:  2022-06-17       Impact factor: 6.208

Review 5.  Analyses of lung cancer-derived volatiles in exhaled breath and in vitro models.

Authors:  Fouad Choueiry; Addison Barham; Jiangjiang Zhu
Journal:  Exp Biol Med (Maywood)       Date:  2022-04-11

6.  Results of Lung Cancer Screening in the Community.

Authors:  John R Handy; Michael Skokan; Erika Rauch; Steven Zinck; Rachel E Sanborn; Svetlana Kotova; Mansen Wang
Journal:  Ann Fam Med       Date:  2020-05       Impact factor: 5.166

7.  Serum Levels of Sirtuin-1 in Patients with Lung Cancer and its Association with Karnofsky Performance Status.

Authors:  Saeed Hosseninia; Aslan Ameli; Mohammad Reza Aslani; Farhad Pourfarzi; Hassan Ghobadi
Journal:  Acta Biomed       Date:  2021-05-12

8.  Implementation of a lung cancer multidisciplinary team standardised template for reporting to general practitioners: a mixed-method study.

Authors:  Nicole M Rankin; Gemma K Collett; Clare M Brown; Tim J Shaw; Kahren M White; Philip J Beale; Lyndal J Trevena; Cleola Anderiesz; David J Barnes
Journal:  BMJ Open       Date:  2017-12-28       Impact factor: 2.692

Review 9.  Polymer-Drug Conjugate, a Potential Therapeutic to Combat Breast and Lung Cancer.

Authors:  Sibusiso Alven; Xhamla Nqoro; Buhle Buyana; Blessing A Aderibigbe
Journal:  Pharmaceutics       Date:  2020-04-29       Impact factor: 6.321

10.  Luteolin Inhibits Tumorigenesis and Induces Apoptosis of Non-Small Cell Lung Cancer Cells via Regulation of MicroRNA-34a-5p.

Authors:  Ze-Qun Jiang; Mu-Han Li; Yue-Mu Qin; Hai-Ying Jiang; Xu Zhang; Mian-Hua Wu
Journal:  Int J Mol Sci       Date:  2018-02-02       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.